Nanotechnology-Boosted Biomaterials for Osteoarthritis Treatment: Current Status and Future Perspectives
Lin Liu,Haifeng Tang,Yanjun Wang
DOI: https://doi.org/10.2147/IJN.S423737
IF: 7.033
2023-09-05
International Journal of Nanomedicine
Abstract:Lin Liu, Haifeng Tang, Yanjun Wang Department of Emergency, Honghui Hospital of Xi'an Jiaotong University, Xi'an, 710054, People's Republic of China Correspondence: Yanjun Wang; Haifeng Tang, Department of Emergency, Honghui Hospital of Xi'an Jiaotong University, 555 Friendship East Road, Nanshaomen, Xi'an City, Shaanxi Province, 710054, People's Republic of China, Email ; Osteoarthritis (OA) is a prevalent global health concern, posing a significant and increasing public health challenge worldwide. Recently, nanotechnology-boosted biomaterials have emerged as a highly promising strategy for OA therapy due to their exceptional physicochemical properties and capacity to regulate pathological processes. However, there is an urgent need for a deeper understanding of the potential therapeutic applications of these biomaterials in the clinical management of diseases, particularly in the treatment of OA. In this comprehensive review, we present an extensive discussion of the current status and future prospects concerning nanotechnology-boosted biomaterials for OA therapy. Initially, we discuss the pathophysiology of OA and the constraints associated with existing treatment modalities. Subsequently, various types of nanomaterials utilized for OA therapy, including nanoparticles, nanofibers, and nanocomposites, are thoroughly discussed and summarized, elucidating their respective advantages and challenges. Furthermore, we analyze recent preclinical and clinical studies that highlight the potential of nanotechnology-boosted biomaterials in OA therapy. Additionally, future research directions in this evolving field are highlighted. By establishing a link between the structural properties of nanotechnology-boosted biomaterials and their therapeutic functions in OA treatment, we aim to foster advances in designing sophisticated nanomaterials for OA, ultimately resulting in improved therapeutic efficacy of OA therapy through translation into clinical setting in the near future. Keywords: nanotechnology, nanomaterials, osteoarthritis, cartilage, RANKL Osteoarthritis (OA), one of the most common degenerative diseases in aging people, is estimated that more than 10% of men and 18% of women over the age of 60 have symptomatic OA worldwide. 1 Of note, due to the high risk of working disability, it also imposes an overwhelming economic burden on individuals, healthcare systems, and societies. 2 OA is distinguished by the progressive deterioration of articular cartilage in the affected joints. The pathophysiology of OA is multifactorial, involving intricate interactions among various elements, including cartilage breakdown, chronic inflammatory responses, alterations in subchondral bone structure, synovial inflammation, and aberrant joint mechanics. 2 The cumulative effect of these processes manifests as pain, joint stiffness, and impaired joint mobility over time. Nonetheless, the current therapeutic options for OA are not without their limitations. Pharmacological interventions, such as nonsteroidal anti-inflammatory drugs (NSAIDs), serve to provide transient pain relief but lack the ability to modify the disease trajectory. 1,3 Additionally, a deficiency of efficacious disease-modifying therapies hampers the ability to effectively slow down or halt the progressive nature of OA. In severe cases, surgical interventions, like joint replacement, offer relief; however, they are characterized by invasiveness and inherent risks. Furthermore, achieving complete restoration of damaged cartilage remains a challenge, with current approaches yielding limited success. Compounding the complexity, the individualized presentation of OA further complicates the pursuit of universally effective treatments. 4,5 Therefore, it is highly desirable to achieve more in-depth knowledge of OA and decipher advanced therapeutic strategies to enhance clinical outcomes of OA therapy. Emerging studies evidenced that there is an increasing demand for precise targeting in OA therapy, and biomaterial-based precision medicine represents a promising strategy for improving the unsatisfactory outcomes of current OA therapies (Figure 1). 6 Importantly, with the excellent stride of development in nanotechnology, nanotechnology-boosted biomaterials have shown great potential in the field of OA therapy. 7,8 The excellent physicochemical properties of nanotechnology-boosted biomaterials, such as high surface area ratio, tunable mechanical properties, and improved biocompatibility, have attracted accumulative interest of developing advanced biomaterials-based strategies for enhancing bone and cartilage regeneration in OA. 9,10 Furthermore, by exploiting the unique properties of nanomaterials, such as their large surface area-to-volume ratio and the ability to modulate their size an -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology